EYE

Source and sharing of nuskin.com 2018.

Pharmanex® Eye Formula is a supplement that contains clinically effective
doses of two powerful carotenoids—lutein and zeaxanthin—and a unique
formula of complementary nutrients that help protect your eyes from
damaging blue light while supporting general eye health.
Your vision champion. Protecting your eye health has never
been more crucial. From sunshine to smart phones and
TV to LED light, your eyes take a daily blue light beating.
Luckily, Pharmanex Eye Formula contains clinically effective
doses of lutein and zeaxanthin—two powerful carotenoids
that help protect your eyes from damaging blue light.
And there are benefits beyond the blue. Your eyes’ lenses
and macula are continually subjected to free-radical-producing
factors—ultraviolet light, for one—and rely on a range of
antioxidants to neutralize the damaging effects. Pharmanex
Eye Formula contains key nutrients that support healthy
eye function, including vitamin C, zinc, and selenium.This
innovative blend of nutrients supports healthy eye function
both now and as you age. It’
s your personal one-two punch
of blue light defense and eye health support.
• Helps protect eyes from blue light.
• May help reduce glare sensitivity.
• Provides support and key nutrients important for eye health
and function.
• Protects cells from oxidative damage.
• Formulated based on the most recent scientific evidence
and studies, including AREDS2.
• Certified to improve Skin Carotenoid Scores.
• A complementary blend of clinically supported lutein and
zeaxanthin—helps provide protection of the macula.
• Unique formulation of complementary nutrients—helps
support eye health and protection.

Many of us likely know about the dangers of ultraviolet light;
however, blue light is becoming a bigger issue in today’
s
world. Blue light is part of the visible light spectrum between
400 and 780 nm. What does that mean? The light we can
see is different from ultraviolet light (280 to 400 nm) and
less energetic infrared wavelengths (780 nm to 1 mm). Of
all the different colors of visible light, blue light is the most
energetic wavelength. That means it has the greatest potential
for causing damage, including causing the formation of
reactive oxygen species (ROS), to the macula of the eye.
And increased ROS may result in significant damage to
cell structures. Basically, overexposure to blue light is bad
news for your eyes.
Absolutely. A landmark clinical trial known as AREDS
monitored the progress of individuals taking a supplement
formulated to support eye health for an average of 6.3 years.
Based on the results of AREDS, the National Eye Institute
launched AREDS2 with modified nutrient amounts and
additional ingredients. In accordance with AREDS2, a
daily dose of Eye Formula delivers the macular carotenoids,
lutein, and zeaxanthin, in clinically effective doses (10 mg
and 2 mg respectively) that help protect your eyes

Is Eye Formula safe?
Yes. Eye Formula is safe and well tolerated at the recommended
dose. Eye Formula contains vitamins and minerals shown in
clinical trials to support structures of the eye. In addition to
vitamins and minerals, Eye Formula contains the macular
carotenoids lutein and zeaxanthin. Each of Eye Formula’
s
ingredients is a common part of the human diet, yet from
diet alone we may not get enough of all of these nutrients
which is why supplementation is so important.
Why is Eye Formula scanner certified?

A daily dose of Pharmanex® Eye Formula contains 10 mg of
lutein and 2 mg of zeaxanthin. Together, these two carotenoids
provide sufficient antioxidant support to guarantee increased
scanner scores. Lutein and zeaxanthin play a critical role in
protecting structures of the eye but are also among the
carotenoids present in skin tissue. Although scanner scores
measure carotenoid concentrations in the skin, to the degree
that they are impacted by the presence of lutein and
zeaxanthin in the skin, scanner scores may also reflect
macular carotenoid status.

You have been invited to join Alexander Vasko team as a Brand Affilite. Click here : http://nskn.co/ZjYzVS 

THE SCIENCE BEHIND IT

1. Mozaffarieh M, Sacu S, Wedrich A. The role of the
carotenoids, lutein and zeaxanthin, in protecting

against age-related macular degeneration: A review
based on controversial evidence. Nutr J 2003;2:20.
2. Bone RA, Landrum JT, Guerra LH, Ruiz CA. Lutein
and Zeaxanthin Dietary Supplements Raise Macular
Pigment Density and Serum Concentrations of these
Carotenoids in Humans. J Nutr 2003;133:992-8.
3. Bernstein PS, Ahmed F, Liu A, Allman S, Sheng X,
Sharifzadeh M, Ermakov I, Gellermann W. Macular
pigment imaging in AREDS2 participants: An ancillary
study of AREDS2 subjects enrolled at the Moran Eye
Center. Invest Ophthalmol Vis Sci. 2012 Aug 9.
4. Richer SP, Stiles W, Graham-Hoffman K, Levin M,
Ruskin D, Wrobel J, Park DW, Thomas C. Randomized,
double-blind, placebo-controlled study of zeaxanthin
and visual function in patients with atrophic age-related
macular degeneration. Optometry. 2011 Nov;82(11):667–
680.e6.
5. Conrady CD, Bell JP, Besch BM, Gorusupudi A,
Farnsworth K, Ermakov I, Sharifzadeh M, Ermakova M,
Gellermann W, Bernstein PS. Correlations Between
Macular, Skin, and Serum Carotenoids. Invest
Ophthalmol Vis Sci. 2017 Jul 1;58(9):3616-3627. doi:
10.1167/iovs.17–21818. PubMed PMID: 28728169;
PubMed Central PMCID: PMC5520678.
6. Stringham JM, Hammond BR. Macular pigment and
visual performance under glare conditions. Optom
Vis Sci. 2008 Feb;85(2):82-8. doi: 10.1097/
OPX.0b013e318162266e. Erratum in: Optom Vis Sci.
2008 Apr;85(4):285. PubMed PMID: 18296924.

7. Hammond BR, Fletcher LM, Roos F, Wittwer J, Schalch
W. A double-blind, placebo-controlled study on the
effects of lutein and zeaxanthin on photostress recovery,
glare disability, and chromatic contrast. Invest Ophthalmol
Vis Sci. 2014 Dec 2;55(12):8583-9. doi: 10.1167/iovs.14–
15573. PubMed PMID: 25468896.
8. AREDS2 Research Group, Chew EY, Clemons T,
SanGiovanni JP, Danis R, Domalpally A, McBee W,
Sperduto R, Ferris FL. The Age-Related Eye Disease
Study 2 (AREDS2): study design and baseline
characteristics (AREDS2 report number 1).
Ophthalmology. 2012 Nov;119(11):2282–9. doi: 10.1016/j.
ophtha.2012.05.027. Epub 2012 Jul 26. PubMed PMID:
22840421; PubMed Central PMCID: PMC3485447